HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

991.991

+14.5711.49%

Number of Gainers:8

Number of Losers:9

Number of Flat:1

PE:- -

High:996.997

Open:977.343

Low:962.881

Close:977.420

Loading ...

CSPC Pharmaceutical Group May Benefit From Higher Success Odds of 'SYS6010' -- Market Talk

Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs

Fosun Pharmaceutical Gets Chinese Regulatory Approval for Breast Cancer Drug; Shares Up 4%

MT Newswires Live

BUZZ-China's CSPC soars on talks of licensing, commercializing products

BRIEF-CSPC Pharmaceutical In Negotiations With Independent Third Parties Regarding Three Transactions

CSPC Pharmaceutical - Potential Transactions May Amount to US$5 Bln in Aggregate

THOMSON REUTERS

CSPC Pharmaceutical - in Negotiations With Certain Independent Third Parties Regarding Three Potential Transactions

THOMSON REUTERS

Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting

Yichang HEC Changjiang Pharmaceutical Co. Ltd. Held Annual General Meeting

China Traditional Chinese Medicine Holdings Announces Auditor Retirement, Seeks Replacement

Ping An Healthcare Proposes EY as New Auditor, Replacing PwC After 7 Years

CSPC Pharmaceutical Group Q1 Revenue RMB 608 Million

THOMSON REUTERS

BRIEF-Guangzhou Baiyunshan Pharmaceutical Announces Capital Increase In Baiyunshan Biological

Guangzhou Baiyunshan Pharmaceutical - Capital Increase in Baiyunshan Biological

THOMSON REUTERS

Yichang Hec Changjiang Pharmaceutical Co. Ltd. Announces Internal Securities Dealings Under Takeovers Code

Sino Biopharm Presents Cancer Drug Data at Oncology Conference

MT Newswires Live

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Ongericimab Injection by Nmpa

THOMSON REUTERS

China Traditional Chinese Medicine Holdings Co. Limited Announces Final Dividend of HKD 0.0035 Per Share for Year Ended 31 December 2024

Fosun Pharmaceutical Gains EU Orphan Drug Status for Cancer Drug

MT Newswires Live

Sino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1515/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":991.99066,"timestamp":1749197315310,"preClose":977.4198,"halted":0,"volume":1056152648,"delay":0,"changeRate":0.014907,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":14.570862,"latestTime":"06-06 16:00:00","open":977.34314,"high":996.9972,"low":962.88086,"amount":8216140914,"amplitude":0.034904,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":1.687745,"peRate":22.554204,"turnoverRate":0.01274,"increases":6,"decrements":11,"flats":1,"marketCap":681715704384,"floatMarketCap":558773810112},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":996.9972,"amplitude":0.034904,"preClose":977.4198,"low":962.88086,"pbRate":"1.687745","latestPrice":991.99066,"volume":1056152648,"delay":0,"open":977.34314,"prevYearClose":787.97723,"prevWeekClose":975.506,"prevMonthClose":975.506,"prevQuarterClose":870.015,"fiveDayClose":975.506,"twentyDayClose":896.528,"sixtyDayClose":938.742,"secType":"PLATE","market":"HK","turnoverRate":0.01274,"peRate":22.554204,"marketCap":681715704384,"floatMarketCap":558773810112,"timestamp":1749197315310,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":8,"down":9,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540904757","title":"CSPC Pharmaceutical Group May Benefit From Higher Success Odds of 'SYS6010' -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2540904757","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540904757?lang=en_us&edition=fundamental","pubTime":"2025-06-02 13:41","pubTimestamp":1748842860,"startTime":"0","endTime":"0","summary":"0541 GMT - CSPC Pharmaceutical Group may benefit from higher success odds of its 'SYS6010' antibody-drug conjugate, China Galaxy International's Lily Wang says in a research report. SYS6010 has demonstrated tolerable safety and promising efficacy in both Epidermal Growth Factor Receptor-mutant and EGFR wild-type non-small cell lung cancer, the analyst notes. Also, management highlighted its business development performance in 2025 could exceed its previous guidance of 2-3 more deals, including at least three out-licensing deals worth over US$5 billion each, the analyst adds. The brokerage raises the stock's target price to HK$10.04 from HK$7.43 with an unchanged add rating. Shares are 6.2% lower at HK$7.60. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","BK1191","SG9999004220.SGD","IE0008369823.USD","LU1951186391.HKD","LU0326950275.SGD","BK1521","LU1226288253.USD","LU0067412154.USD","LU0501845795.SGD","IE00BZ08YR35.GBP","LU1226287529.USD","LU1152091168.USD","IE0008368742.USD","01093","BK1515","LU1226287875.USD","LU1960683339.HKD","LU0880133367.SGD","LU1807302812.USD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU0072913022.USD","LU1152091754.HKD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE00B031HY20.USD","LU1008478684.HKD","LU1226288170.HKD"],"gpt_icon":1},{"id":"2539275394","title":"Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275394","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539275394?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:43","pubTimestamp":1748616210,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has been involved in legal proceedings with Viking Therapeutics, Inc. over the importation of its drug candidates, ASC41 and ASC43F. In October 2024, the United States International Trade Commission issued an initial determination finding a violation of Section 337, recommending a seven-year exclusion order for these drugs. ASC41 is developed for treating non-alcoholic steatohepatitis  and targets thyroid hormone receptor beta , while ASC43F is a fixed-dose combination targeting both THRβ and farnesoid X receptor  for NASH treatment. Despite the ruling, Ascletis believes the outcome will not have a material adverse effect on its business and is seeking legal advice for an appeal. The company is committed to protecting its trade secrets and will provide updates on any significant developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL48bdv9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1574","BK4139","BK4588","BK1161","VKTX","BK1515","BK4599","BK4585"],"gpt_icon":0},{"id":"2539219128","title":"Fosun Pharmaceutical Gets Chinese Regulatory Approval for Breast Cancer Drug; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539219128","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539219128?lang=en_us&edition=fundamental","pubTime":"2025-05-30 11:19","pubTimestamp":1748575161,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Jinzhou Aohong Pharmaceutical received the approval of China's drug administrator for its citrate-formulated novel drug FCN-437c in capsule form, according to a Thursday filing with the Shanghai bourse.The approved indication is in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer following prior endocrine therapy.Shares of the pharmaceutical company rose 4% in recent trade on the Shanghai bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","600196","BK0239","BK0187","BK0183","BK0196","BK0175","BK1515","BK1593","BK1230","BK0188","02196","BK0028","BK0060","BK1191","BK0012","00656"],"gpt_icon":0},{"id":"2539219531","title":"BUZZ-China's CSPC soars on talks of licensing, commercializing products","url":"https://stock-news.laohu8.com/highlight/detail?id=2539219531","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539219531?lang=en_us&edition=fundamental","pubTime":"2025-05-30 11:09","pubTimestamp":1748574588,"startTime":"0","endTime":"0","summary":"BUZZ-China's CSPC soars on talks of licensing, commercializing products** Shares of CSPC Pharmaceutical Group 1093.HK jump 12.3% to HK$8.56, their highest since March 2023** Stock set for the biggest one-day pct rise since November 2022; top pct gainer in the Hang Seng Index .HSI** CSPC said it is in negotiations with independent third parties on three transactions involving license, collaboration in development, manufacturing and commercialization of certain products with upfront payments amounting to an aggregate $5 bln** Hong Kong's healthcare index .HSCIH climbs 0.5%, Hang Seng Biotech Index .HSHKBIO gains 0.8%** YTD, stock up 72.4%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nL2N3S202I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU1993786604.SGD","LU1226287875.USD","LU0140636845.USD","LU1807302812.USD","LU0501845795.SGD","IE00BZ08YR35.GBP","BK1521","LU0880133367.SGD","LU1226288253.USD","LU0072913022.USD","LU1152091168.USD","LU1951186391.HKD","IE0008368742.USD","LU1226287792.SGD","LU0067412154.USD","IE00B543WZ88.USD","LU1008478684.HKD","IE0008369823.USD","LU1226288170.HKD","SG9999004220.SGD","IE00BZ08YS42.EUR","BK1191","01093","IE00BZ08YT58.USD","LU1152091754.HKD","LU1960683339.HKD","IE00B031HY20.USD","BK1515","LU1226287529.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2539900952","title":"BRIEF-CSPC Pharmaceutical In Negotiations With Independent Third Parties Regarding Three Transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2539900952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539900952?lang=en_us&edition=fundamental","pubTime":"2025-05-30 09:21","pubTimestamp":1748568068,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical In Negotiations With Independent Third Parties Regarding Three TransactionsMay 30 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:IN NEGOTIATIONS WITH CERTAIN INDEPENDENT T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S12SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","LU0072913022.USD","BK1521","LU1008478684.HKD","LU0067412154.USD","IE00BZ08YT58.USD","01093","IE00B543WZ88.USD","IE00B031HY20.USD","BK1515","LU1807302812.USD","LU0880133367.SGD","LU1152091168.USD","LU0326950275.SGD","LU1226288170.HKD","SG9999004220.SGD","BK1191","IE00BZ08YR35.GBP","LU1226287875.USD","LU1226288253.USD","IE00BZ08YS42.EUR","LU1960683339.HKD","LU0140636845.USD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU1226287529.USD","LU1993786604.SGD","IE0008368742.USD","IE0008369823.USD","LU1951186391.HKD","LU1226287792.SGD"],"gpt_icon":0},{"id":"2539925732","title":"CSPC Pharmaceutical - Potential Transactions May Amount to US$5 Bln in Aggregate","url":"https://stock-news.laohu8.com/highlight/detail?id=2539925732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539925732?lang=en_us&edition=fundamental","pubTime":"2025-05-30 08:07","pubTimestamp":1748563621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S12SD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B031HY20.USD","01093","LU1993786604.SGD","BK1521","LU1152091754.HKD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU1008478684.HKD","IE00BZ08YT58.USD","LU0326950275.SGD","IE0008368742.USD","LU0067412154.USD","LU0880133367.SGD","IE0008369823.USD","LU1807302812.USD","LU0501845795.SGD","BK1191","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU1226288253.USD","LU1226287875.USD","LU0072913022.USD","IE00B5MMRT66.SGD","LU1951186391.HKD","LU1152091168.USD","BK1515","SG9999004220.SGD","LU1226287529.USD","LU0140636845.USD","LU1226288170.HKD","LU1960683339.HKD"],"gpt_icon":0},{"id":"2539292575","title":"CSPC Pharmaceutical - in Negotiations With Certain Independent Third Parties Regarding Three Potential Transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2539292575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539292575?lang=en_us&edition=fundamental","pubTime":"2025-05-30 08:07","pubTimestamp":1748563621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S12SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","LU1993786604.SGD","LU1226287875.USD","LU0140636845.USD","LU1807302812.USD","LU0501845795.SGD","IE00BZ08YR35.GBP","BK1521","LU0880133367.SGD","LU1226288253.USD","LU0072913022.USD","LU1152091168.USD","LU1951186391.HKD","IE0008368742.USD","LU1226287792.SGD","LU0067412154.USD","IE00B543WZ88.USD","LU1008478684.HKD","IE0008369823.USD","LU1226288170.HKD","SG9999004220.SGD","IE00BZ08YS42.EUR","BK1191","01093","IE00BZ08YT58.USD","LU1152091754.HKD","LU1960683339.HKD","IE00B031HY20.USD","BK1515","LU1226287529.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2539250463","title":"Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250463","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250463?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:23","pubTimestamp":1748521386,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLbJ1hqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","01177","IE00BZ08YR35.GBP","BK1191","BK1521","IE00BZ08YT58.USD","BK1515","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2539510952","title":"Yichang HEC Changjiang Pharmaceutical Co. Ltd. Held Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539510952","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539510952?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:48","pubTimestamp":1748515690,"startTime":"0","endTime":"0","summary":"Yichang Hec Changjiang Pharmaceutical Co. Ltd. held its Annual General Meeting on May 29, 2025. During the meeting, several proposals were reviewed and approved. These included the re-appointment of KPMG as auditor for a term until the next annual general meeting, the report of the Board of Directors for the year ended December 31, 2024, and the report of the Supervisory Committee for the same period. Additionally, the audited consolidated financial statements for the year ended December 31, 2024, were approved, as well as the profit distribution plan for the year. All proposals were passed as ordinary resolutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yichang Hec Changjiang Pharmaceutical Co. Ltd. published the original conte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL8PJDVy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","01558"],"gpt_icon":0},{"id":"2539237806","title":"China Traditional Chinese Medicine Holdings Announces Auditor Retirement, Seeks Replacement","url":"https://stock-news.laohu8.com/highlight/detail?id=2539237806","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539237806?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:44","pubTimestamp":1748508250,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited announced the retirement of its auditor, Ernst & Young (E&Y), due to regulatory requirements limiting the duration an accounting firm can provide auditing services to central state-owned enterprises and their subsidiaries. As a subsidiary of China National Pharmaceutical Group Co., Ltd., the company is subject to these regulations. E&Y had not yet commenced audit work for the financial year ending December 31, 2025, and the Board confirmed that this change would not significantly impact the annual audit and results release. The company is actively seeking a suitable replacement and will announce the new auditor when appointed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLYLjp0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","00570","BK1515"],"gpt_icon":0},{"id":"2539321082","title":"Ping An Healthcare Proposes EY as New Auditor, Replacing PwC After 7 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2539321082","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539321082?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:38","pubTimestamp":1748507911,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ping An Healthcare and Technology Co. Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL5MyNb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK0070","601318","LU0456846285.SGD","BK0032","LU0051755006.USD","BK0175","01833","LU1934453819.USD","BK1615","BK0196","BK1142","BK1219","LU1781817850.SGD","LU1655091616.SGD","BK1247","LU0405327494.USD","BK0012","LU1997245094.SGD","SG9999002463.SGD","LU0326950275.SGD","LU1820825898.SGD","LU1064130708.USD","LU1064131003.USD","BK0183","BK0028","LU1979443071.USD","LU2289578879.USD","LU2495084118.USD","LU2148510915.USD","BK1571","LU0405327148.USD","LU1146622755.USD","LU0047713382.USD","BK1515","BK0188","IE0005HP3H50.USD","LU2213484517.USD","LU1997245177.USD","LU1580142542.USD","LU0039217434.USD","BK0207","LU2328871848.SGD","LU0456827905.SGD","LU1997244956.HKD","BK1617","BK0187"],"gpt_icon":0},{"id":"2539287514","title":"CSPC Pharmaceutical Group Q1 Revenue RMB 608 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2539287514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539287514?lang=en_us&edition=fundamental","pubTime":"2025-05-29 12:00","pubTimestamp":1748491258,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nPLX413457:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1152091754.HKD","SG9999004220.SGD","LU1008478684.HKD","IE0008369823.USD","BK1515","LU1226287875.USD","LU1152091168.USD","01093","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","LU1226287792.SGD","LU0501845795.SGD","LU0067412154.USD","LU0140636845.USD","IE00B031HY20.USD","LU1951186391.HKD","IE0008368742.USD","BK1191","IE00BZ08YS42.EUR","BK1521","LU1960683339.HKD","LU1226288170.HKD","LU0072913022.USD","LU1226288253.USD","IE00BZ08YT58.USD","LU1807302812.USD","LU0326950275.SGD","LU0880133367.SGD","LU1226287529.USD","IE00B543WZ88.USD","LU1993786604.SGD"],"gpt_icon":0},{"id":"2538791422","title":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Announces Capital Increase In Baiyunshan Biological","url":"https://stock-news.laohu8.com/highlight/detail?id=2538791422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538791422?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:21","pubTimestamp":1748427670,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Announces Capital Increase In Baiyunshan BiologicalMay 28  - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:CAPITAL INCREASE IN BAIYUNSHAN BIOLOGICALUPON COMPLETION, REGISTERED CAPITAL OF BAIYUNSHAN BIOLOGICAL TO INCREASE TO RMB120.535909 MILLIONFurther company coverage: 600332.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0188","BK1521","00874","BK1191","BK0196","BK0070","BK1197","BK0097","BK0239","BK0183","600332","BK0096","BK0012","BK0028","BK1606","BK1515"],"gpt_icon":0},{"id":"2538424771","title":"Guangzhou Baiyunshan Pharmaceutical - Capital Increase in Baiyunshan Biological","url":"https://stock-news.laohu8.com/highlight/detail?id=2538424771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538424771?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:01","pubTimestamp":1748426495,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600332","00874","BK0188","BK1197","BK0239","BK0196","BK0028","BK0012","BK0070","BK0096","BK0097","BK0183","BK1191","BK1521","BK0175","BK1606","BK1515"],"gpt_icon":0},{"id":"2538422556","title":"Yichang Hec Changjiang Pharmaceutical Co. Ltd. Announces Internal Securities Dealings Under Takeovers Code","url":"https://stock-news.laohu8.com/highlight/detail?id=2538422556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538422556?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:01","pubTimestamp":1748426473,"startTime":"0","endTime":"0","summary":"Yichang Hec Changjiang Pharmaceutical Co. Ltd. announced securities dealings under the Hong Kong Code on Takeovers and Mergers. On May 27, 2025, CICC Financial Trading Limited executed transactions involving Delta 1 products and ordinary shares. The dealings were linked to unsolicited client-driven orders, involving the sale and purchase of 342,800 shares. CICC Financial Trading Limited is an exempt principal trader connected with the Offeror and is owned by China International Capital Corporation Limited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yichang Hec Changjiang Pharmaceutical Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL40mdqx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","601995","BK1191","BK0276","01558"],"gpt_icon":0},{"id":"2538445804","title":"Sino Biopharm Presents Cancer Drug Data at Oncology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538445804","media":"MT Newswires Live","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538445804?lang=en_us&edition=fundamental","pubTime":"2025-05-28 15:13","pubTimestamp":1748416438,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  presented preliminary data from its first-in-human Phase I clinical study of cancer drug TQB2102 at the 2025 ASCO Annual Meeting, according to a Tuesday filing with the Hong Kong Exchange.The company reported encouraging results, with response rates of up to 70% in certain HER2-positive cancers, including breast and gastric cancers -- even among patients who had not responded to prior treatments.Side effects were described as manageable, with only a few cases of serious lung-related adverse events.TQB2102 is currently in Phase 3 trials and, if successful, could become the world's first approved bispecific HER2 antibody-drug conjugate , the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","01177","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK4231","ADC.AU","BK1521","BK1589","BK1191","BK7095","IE00BZ08YS42.EUR","BK4080","BK1515"],"gpt_icon":0},{"id":"2538465968","title":"Shanghai Junshi Biosciences -  Approval of Supplemental New Drug Application for Ongericimab Injection by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465968?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:53","pubTimestamp":1748346824,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ10I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01877","688180","BK1161","BK1583","BK0239","BK1515"],"gpt_icon":0},{"id":"2538463315","title":"China Traditional Chinese Medicine Holdings Co. Limited Announces Final Dividend of HKD 0.0035 Per Share for Year Ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2538463315","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538463315?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:17","pubTimestamp":1748344645,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited Announces Final Dividend of HKD 0.0035 Per Share for Year Ended 31 December 2024. China Traditional Chinese Medicine Holdings Co. Limited has announced a final dividend of HKD 0.0035 per share for the financial year ended 31 December 2024. The announcement was updated on 27 May 2025, with shareholders' approval scheduled for 27 June 2025. The ex-dividend date is set for 03 July 2025, with a payment date of 18 July 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief on May 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL5490b0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1606","00570","BK1191"],"gpt_icon":0},{"id":"2538243520","title":"Fosun Pharmaceutical Gains EU Orphan Drug Status for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2538243520","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538243520?lang=en_us&edition=fundamental","pubTime":"2025-05-27 12:42","pubTimestamp":1748320947,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said its anti-HER2 drug HLX22 was granted orphan drug designation by the European Commission.The drug is used for gastric and breast cancer treatment.Further clinical trials and regulatory approvals are required before commercialization.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0196","BK4156","BK0096","02196","BK0187","BK1191","BK0183","BK1593","BK0012","BK0188","BK1515","600196","BK0175","BK0239","00656","BK0028"],"gpt_icon":0},{"id":"2537135011","title":"Sino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537135011","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537135011?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:50","pubTimestamp":1748001055,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  presented the latest results of a Benmelstobart injection study to treat advanced squamous non-small cell lung cancer at the 2025 American Society of Clinical Oncology  Annual Meeting, a Friday Hong Kong bourse filing said.The phase III clinical trial studies the use of the drug in combination with chemotherapy, followed by sequential combination with Anlotinib Hydrochloride capsules, versus the Tislelizumab injection in combination with chemotherapy.The trial shows that the drug in combination with the other therapies significantly prolonged median progression-free survival compared with Tislelizumab, reducing the risk of disease progression or death by 36% in the trial group.The overall safety of the trial group was also good.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1589","01177","IE00BZ08YR35.GBP","BK1191","BK1521","IE00BZ08YT58.USD","BK1515","IE00BZ08YS42.EUR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}